CRNX CRINETICS PHARMACEUTICALS INC Product Launches 8-K Filing 2024 - Phase 2 Study Results Crinetics Pharmaceuticals announced positive results from its Phase 2 study of paltusotine for the treatment of acromegaly and carcinoid syndrome.Get access to all SEC 8-K filings of the CRINETICS PHARMACEUTICALS INC